her2 pulsed dendritic cell vaccine

The HER2 pulsed dendritic cell vaccine is an investigational autologous cellular immunotherapy designed to stimulate the immune system to recognize and attack cancer cells expressing human epidermal growth factor receptor 2 (HER2). The therapy involves isolating a patient's mononuclear cells via apheresis, differentiating them into type-1 polarized dendritic cells ex vivo, and then "pulsing" these cells with HER2 antigen. The matured, antigen-loaded dendritic cells are then administered back to the patient as a therapeutic cancer vaccine. This approach aims to induce or enhance anti-HER2 T-cell responses in patients with HER2-positive cancers such as metastatic breast cancer or high-risk bladder cancer. In some clinical protocols, this vaccination is combined with other agents (e.g., trastuzumab or pepinemab) and may be followed by adoptive transfer of ex vivo expanded HER2-specific T-cells[3][5][7].

Other names

HER2-pulsed autologous type-1 polarized dendritic cell vaccineHER-2-pulsed autologous type-1 polarized dendritic cell vaccineHER 2-pulsed autologous type-1 polarized dendritic cell vaccineHER2-pulsed DC1 vaccineHER-2-pulsed DC1 vaccineHER 2-pulsed DC1 vaccineAdHER2 DC vaccineAdHER-2 DC vaccineAdHER 2 DC vaccine